From Lab to Field: Commercialising Novel Oilfield Technologies

Almost every useful oilfield technology I have commercialised looked, at the bench, like it was already finished. That is the deceit of lab work. A 50 ml beaker behaves itself; a 200-millimetre flowline at 140 degrees Celsius with multiphase slugging and a quarter-percent sand load does not. The honest version of the lab-to-field journey is that the lab is roughly fifteen per cent of the work, the rest is what happens between a clean datasheet and a piece of chemistry that an operator will actually run.

I have been on both sides of this transit. At Aramco's Advanced Research Centre I led the commercialisation of several novel production chemistry technologies, including the thermochemical fluids platform that earned the corporate Innovation Board Award and one of two World Oil Awards I have been fortunate to receive. The pattern that emerged across those projects, and across roughly fifty patents that followed, is the subject of this piece.

Why most oilfield innovations die in the gap

The standard narrative is that promising oilfield R&D dies because it is too expensive to scale or because operators are conservative. Both are partly true. The deeper reason, in my experience, is that the lab work answers the wrong question. It answers 'does the chemistry do the thing?' when the field is asking 'does the chemistry do the thing under conditions I can actually create, with logistics I can actually run, on a risk profile my asset team will actually accept?'

Those are different questions and they require different evidence. A new friction reducer that performs beautifully in a Fann viscometer means nothing until it has been sheared through a real frac pump for the equivalent of a full stage and re-tested for residual viscosity. A new acid diverter that looks elegant in a core flood means nothing until it has been mixed at -2 degrees Celsius on a winter morning at the wellsite by a crew that has never seen it before.

"The reservoir is not a reviewer. It does not award partial credit for elegant chemistry that fails on a Tuesday morning at the pad."

The four scale gaps that quietly kill technologies

Across the technologies I have moved from concept to deployment, the failures clustered into four scale gaps. None of them are mysterious; almost all of them get postponed until the field trial, where they become very expensive.

• Thermal scale: a 30-minute beaker test at 90 degrees does not predict a 30-day exposure in a flowline that cycles between 110 and 140 degrees with intermittent water breakthrough.
• Hydraulic scale: laminar mixing on a magnetic stirrer behaves nothing like turbulent injection at a wellhead, and many surfactant systems lose their effective HLB under field shear.
• Logistics scale: a chemistry that needs nitrogen blanketing at the pad, or that has a 30-day shelf life in 50-degree summer heat, will not make it through a real supply chain.
• Decision-making scale: a lab team that can accept a 70 per cent success rate in screening cannot survive a 70 per cent success rate in field trials, where each failure is a workover.

Closing each of those gaps requires deliberate work that is rarely funded inside a research budget. That is the structural reason novel oilfield technologies underperform their potential: the people best placed to anticipate the gaps are not the people writing the next research proposal.

A worked example: the thermochemical breakthrough

The technology I am best known for is a thermochemical system that generates heat and pressure in situ to remove near-wellbore damage and stimulate tight intervals. At the bench it was, frankly, dramatic. The reaction kinetics on a 100 ml scale produced exactly the temperature spike the modelling predicted. Six months later, in the first field trial, the system underperformed by roughly 40 per cent.

The reason was unglamorous. The reactant mixing in the wellbore was nothing like the mixing in our reactors. Density contrasts and the time required for the two reactant streams to interpenetrate in a real annulus meant that a meaningful fraction of the chemistry never reacted at all. We rebuilt the deployment as a sequenced injection with a tuned spacer, ran it again on a different well, and recovered the predicted thermal output. Four years and a dozen field deployments later it was generating more than $500 million in attributable production value across the asset base.

The lesson was not that the bench work was wrong. The bench work was correct. The lesson was that the bench work was incomplete in a way that was completely invisible to the bench. That gap is the work of commercialisation.

What real commercialisation work looks like

When Aontas Advisory engages on commercialising a novel chemistry or process, the structure is fairly disciplined. The phases are not always sequential, but they are always present.

1. 01Field-condition replication: a laboratory programme that re-tests the technology under the actual thermal, hydraulic, and chemical envelope of the target asset, not the envelope of the original research programme.
2. 02Failure-mode interrogation: a deliberate effort to break the chemistry under realistic stresses (shear, contaminants, dilution, storage), so that the failure modes are documented before the field trial rather than during it.
3. 03Field-trial design: a single-well or limited-pad deployment with pre-agreed success criteria, baseline data, and a rollback plan. No 'we'll see how it goes' trials.
4. 04Logistics and HSE engineering: the unsexy work of packaging, MSDS, transport classification, on-site handling, and operator training, done before the trial rather than after.
5. 05Scale-up and supply: working with a manufacturing partner whose batch repeatability is documented, not promised.

The operator's side of the bargain

Commercialisation is not a one-sided exercise. The operators who get the most value from novel technologies are the ones who treat the trial as a joint engineering project rather than a vendor demonstration. The Aramco model that I worked inside, and that I have since seen replicated at ADNOC and KOC, has a few hallmarks worth naming.

• A named asset engineer who owns the trial outcome, not just a procurement contact.
• Pre-trial baselining of production data, with enough fidelity that a real signal-to-noise comparison is possible.
• Clear go/no-go criteria written before the chemistry arrives at the wellsite.
• A willingness to share unredacted post-trial data with the technology partner, even when the trial underperforms.
• An understanding that the second deployment is usually where the technology earns its keep, not the first.

Where those conditions are absent, even strong technologies fail to land. Where they are present, modest technologies often find unexpected applications.

What the patent record actually teaches

Of the patents I am named on, perhaps two-thirds describe chemistry that worked exactly as filed. The remaining third describe chemistry that worked, but in a different application than originally envisioned, or with a deployment method that was discovered in the field rather than the lab. The patent record is, in effect, a log of what the lab thought it had invented and what the field eventually accepted.

"Patents are an account of intent. Field deployments are an account of fit. The two converge slowly and only with discipline."

That gap between intent and fit is the territory we work in. It is where the difference between a published paper and a deployed barrel of protected production actually lives.

Closing: who should attempt this

Not every novel chemistry is worth commercialising, and not every operator should be a launch customer for one. The technologies that travel from lab to field successfully tend to share a few characteristics: a clearly defined field problem that catalogue chemistry has not solved, a measurable success criterion that the operator can recognise within twelve months, and a partner team willing to share the engineering risk through the first two or three deployments.

If you are sitting on promising bench-scale work and looking at the wall between you and the first field deployment, that wall is exactly the one our commercialisation practice was built to close. The work is at /services/chemistry, and the conversation usually starts with your existing data, not ours.